In this webinar you will have an overview of the main non-F tracers used in prostate cancer PET-CT Imaging, namely 11C-labelled radiopharmaceuticals (choline and acetate) and 68Ga-labelled tracers (PSMA). We will go through the main features of synthesis and production, clinical indications, patient preparation and scanning protocols. Diagnostic images from real clinical cases will complement the written information and give explanation of the possible clinical findings. Principles of quantification and integration of different imaging techniques are also introduced.
Content: Presentation and MCQ test (6 questions)
Brief summary of contents
This track provides a comprehensive and evidence-based overview of the current state of radionuclide therapy based on alpha emitters for prostate cancer. After a short introduction about the main epidemiological and clinical features of skeletal metastases from prostate cancer, the properties of alpha-particles and the “historical” radiopharmaceuticals used in this field; the core of this lecture focuses on radionuclide therapy based on radium-223. The radium-223 therapy will be discussed in terms of physical, biological and clinical properties showing some specially selected interactive cases that will help to understand better the theoretical issues. The last part of the track include a short view of new possible radiopharmaceuticals with therapeutic action in prostate cancer.
Content: Presentation and MCQ test (7 questions)
Brief summary of contents
The aim of the chapter is to introduce the nuclear medicine practitioner to the trajectory that the patient follows from diagnosis to treatment. There are many stages involved, and all should be tailored to the specific patient. The role of the technologist play an important part in the understanding of the patient, when he attends a nuclear medicine examination.
Content: Presentation and MCQ test (5 questions)
The present webinars has the aims to describe how preclinical studies about prostate cancer are conducted and to provide general knowledge of animal models, to identify the relevance of animal care in the context of preclinical imaging and therapy studies, and to get technologists acquainted with the extended competences needed as a member of a pre-clinical team. Moreover, the impact of nuclear medicine techniques in pre-clinical trials and the problem of the translation from animals to men will be discussed. Finally, some future challenges and opportunities for prostate cancer management will be included.